IQ-AI Regulatory News (IQAI)

IQ-AI Ltd

​

("IQ-AI" or the "Company")

Imaging Biometrics and Prism Clinical Imaging Secure First Installation

The combined technologies will enhance neurosurgical planning and treatment strategies

Imaging Biometrics (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), is pleased to announce the successful first installation of its bundled technologies in partnership with Prism Clinical Imaging, Inc. (Prism), at a major Southeastern US health system. Prism, recognized for its expertise in brain mapping software and applications, and IB, a leading provider of quantitative imaging solutions, have collaborated to deliver advanced tools that support the diagnosis of brain diseases and improve treatment planning. This marks the first installation under the partnership between Prism and IB. The integrated technologies combine brain mapping and analysis tools for clinical use in diagnosing brain disease and guiding treatment.

The comprehensive suite of tools offered by IB and Prism help clinicians treat brain tumor patients by identifying structures to avoid when navigating to a tumor site (Prism) and, once there, distinguishing between aggressive tumor and non-tumor tissue (IB) to aid biopsy and tumor resection planning. By providing detailed images of brain activity and tumor physiology, the combined technologies allow neurosurgeons to plan the safest and optimal surgical approach while preserving functions like speech, movement, and sight. The goal is to keep post-operative defects to a minimum and maximize overall prognosis.

Functional magnetic resonance imaging (fMRI) is experiencing growth driven by the increasing prevalence of neurological disorders and the rising demand of diagnostic tools. The advanced technologies offered by Prism and IB are cutting-edge solutions for healthcare providers which can enhance patient care and clinical outcomes.

--ENDS--

 The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

IQ-AI Ltd

Trevor Brown/Dr Musella/Brett Skelly/Michael Schmainda

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Tel: 020 7220 9797

About Imaging Biometrics®, LLC:  IB is a wholly-owned subsidiary of IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com. Follow IB on Twitter, @IQAI_IB.

About Prism Clinical Imaging®, Inc: Prism provides clinicians with imaging tools to diagnose and plan treatment for brain disorders including tumors, epilepsy, and other neurological disorders. Deployment options range from on-premises to cloud-based. Please visit www.prismclinical.com for further information. Follow Prism on LinkedIn and Twitter, @PrismClinical.